Antiphospholipid syndrome (APS) is an autoimmune thrombophilia propelled by circulating
antiphospholipid antibodies that herald vascular thrombosis and obstetrical complications …

Systemic lupus erythematosus (SLE) is a potentially fatal multiorgan inflammatory disease
that primarily affects females. Due to the heterogeneity of clinical manifestations and lack of …

INTRODUCTION: Patients with chronic kidney disease exhibit features of a hypercoagulable
state and have endothelial dysfunction, which may contribute to their increased …

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent
arterial or venous thrombosis and/or pregnancy losses, in the presence of persistently …

Inhibition of tissue factor pathway inhibitor type 1 (TFPI) is one of the mechanisms by which
lupus anticoagulants (LA) may upregulate tissue factor (TF) activity. We wanted to examine …

Monitoring warfarin anticoagulation in patients with thrombotic antiphospholipid syndrome
(APS) may be complicated by the sensitivity of different thromboplastins to lupus …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition
characterized with chronic organized thrombi that obstruct the pulmonary vessels, leading to …

Introduction 3. Role of TF-initiated blood coagulation in thrombosis 4. Direct contribution to
thrombogenesis 4.1. Fibrin" thrombosis 4.2. Anti-fibrinolytic relevance 4.3. Platelet …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by a
persistently high titer of antiphospholipid antibodies (aPLs). In addition to pregnancy …

Background Tissue factor pathway inhibitor (TFPI) antibodies, which have been reported in
patients with antiphospholipid syndrome (APS), may impair TFPI activity and contribute to …